Home LiteratureArticle Details
PMID: 25222559 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance.

Genome biology ·Vol. 15 ·No. 8 ·2014-08-30 ·Pages 449

Siravegna G, Bardelli A

Abstract

DNA fragments released from cancer cells into the blood can be used to generate molecular profiles of tumors. Non-invasive 'liquid biopsies' can be used to monitor minimal residual disease and detect the emergence of drug resistance.

MeSH Terms
Cell-Free System DNA, Neoplasm/analysis Drug Resistance, Neoplasm Genotype Humans Neoplasm, Residual/diagnosis Neoplasms/blood,genetics,pathology
Chemicals
DNA, Neoplasm
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Siravegna Giulia
Bardelli Alberto
References (52)
52 references, click to expand
  1. Liquid biopsies: genotyping circulating tumor DNA.
    J Clin Oncol. 2014 Feb 20;32(6):579-86 PMID: 24449238
  2. TP53 gene mutations in plasma DNA of cancer patients.
    Genes Chromosomes Cancer. 1999 Feb;24(2):160-1 PMID: 9885984
  3. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients.
    Br J Cancer. 1999 Jun;80(8):1262-4 PMID: 10376981
  4. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.
    Ann N Y Acad Sci. 2008 Aug;1137:190-6 PMID: 18837946
  5. Circulating mutant DNA to assess tumor dynamics.
    Nat Med. 2008 Sep;14(9):985-90 PMID: 18670422
  6. Exosomes: the future of biomarkers in medicine.
    Biomark Med. 2013 Oct;7(5):769-78 PMID: 24044569
  7. Real-time liquid biopsy in cancer patients: fact or fiction?
    Cancer Res. 2013 Nov 1;73(21):6384-8 PMID: 24145355
  8. Circulating nucleic acids in plasma and serum. Recent developments.
    Ann N Y Acad Sci. 2008 Aug;1137:1-6 PMID: 18837917
  9. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease.
    Cancer. 1983 Jun 1;51(11):2116-20 PMID: 6188527
  10. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer.
    Gastroenterology. 1997 Apr;112(4):1114-20 PMID: 9097993
  11. Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus.
    J Clin Invest. 1980 Dec;66(6):1391-9 PMID: 7440721
  12. Detection and quantification of mutations in the plasma of patients with colorectal tumors.
    Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 PMID: 16258065
  13. Free DNA in serum and plasma from normal adults.
    J Clin Invest. 1975 Aug;56(2):512-5 PMID: 1150882
  14. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
    N Engl J Med. 2013 Mar 28;368(13):1199-209 PMID: 23484797
  15. Circulating nucleic acids (CNAs) and cancer--a survey.
    Biochim Biophys Acta. 2007 Jan;1775(1):181-232 PMID: 17137717
  16. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
    Nature. 2013 May 2;497(7447):108-12 PMID: 23563269
  17. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.
    Nucleic Acids Res. 2010 Oct;38(18):6159-75 PMID: 20494973
  18. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
    Nature. 2012 Jun 28;486(7404):537-40 PMID: 22722843
  19. Effects of preanalytical factors on the molecular size of cell-free DNA in blood.
    Clin Chem. 2005 Apr;51(4):781-4 PMID: 15708950
  20. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
    PLoS Genet. 2014 Mar 27;10(3):e1004271 PMID: 24676216
  21. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA.
    Oncotarget. 2013 Oct;4(10):1856-7 PMID: 24196513
  22. Free DNA in the serum of cancer patients and the effect of therapy.
    Cancer Res. 1977 Mar;37(3):646-50 PMID: 837366
  23. Analysis of circulating tumor DNA to confirm somatic KRAS mutations.
    J Natl Cancer Inst. 2009 Sep 16;101(18):1284-5 PMID: 19641175
  24. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
    Ann N Y Acad Sci. 2004 Jun;1022:76-80 PMID: 15251943
  25. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.
    Br J Haematol. 1994 Apr;86(4):774-9 PMID: 7918071
  26. Targeted therapies: how personal should we go?
    Nat Rev Clin Oncol. 2011 Nov 15;9(2):87-97 PMID: 22083042
  27. Changes in concentration of DNA in serum and plasma during storage of blood samples.
    Clin Chem. 2003 Jun;49(6 Pt 1):1028-9 PMID: 12766024
  28. Double-stranded DNA in exosomes: a novel biomarker in cancer detection.
    Cell Res. 2014 Jun;24(6):766-9 PMID: 24710597
  29. Tracking tumor resistance using 'liquid biopsies'.
    Nat Med. 2013 Jun;19(6):676-7 PMID: 23744147
  30. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
    Ann N Y Acad Sci. 2008 Aug;1137:171-4 PMID: 18837943
  31. Microsatellite alterations in plasma DNA of small cell lung cancer patients.
    Nat Med. 1996 Sep;2(9):1033-5 PMID: 8782463
  32. Cancer detection using whole-genome sequencing of cell free DNA.
    Oncotarget. 2013 Aug;4(8):1119-20 PMID: 23912395
  33. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma.
    Transfusion. 2001 Feb;41(2):276-82 PMID: 11239235
  34. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.
    Cancer Res. 2001 Feb 15;61(4):1659-65 PMID: 11245480
  35. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
    Clin Cancer Res. 2014 May 15;20(10):2643-2650 PMID: 24504125
  36. Detection of circulating tumor DNA in early- and late-stage human malignancies.
    Sci Transl Med. 2014 Feb 19;6(224):224ra24 PMID: 24553385
  37. Circulating tumor DNA to monitor metastatic breast cancer.
    N Engl J Med. 2013 Jul 4;369(1):93-4 PMID: 23822788
  38. Soluble normal and mutated DNA sequences from single-copy genes in human blood.
    Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71 PMID: 8118388
  39. Neoplastic characteristics of the DNA found in the plasma of cancer patients.
    Oncology. 1989;46(5):318-22 PMID: 2779946
  40. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum.
    Ann N Y Acad Sci. 2000 Apr;906:8-12 PMID: 10818587
  41. Nuclear Acids In Human Blood Plasma.
    C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3 PMID: 18875018
  42. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.
    Anticancer Res. 2002 Jan-Feb;22(1A):421-5 PMID: 12017326
  43. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
    Int J Cancer. 2011 Jun 1;128(11):2572-80 PMID: 20715113
  44. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Nature. 2012 Jun 28;486(7404):532-6 PMID: 22722830
  45. Microsatellite alterations in serum DNA of head and neck cancer patients.
    Nat Med. 1996 Sep;2(9):1035-7 PMID: 8782464
  46. Isolation of biologically-active exosomes from human plasma.
    J Immunol Methods. 2014 Sep;411:55-65 PMID: 24952243
  47. Circulating cell free DNA: Preanalytical considerations.
    Clin Chim Acta. 2013 Sep 23;424:222-30 PMID: 23727028
  48. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
    BJU Int. 2006 Sep;98(3):544-8 PMID: 16925751
  49. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.
    Clin Chim Acta. 2001 Nov;313(1-2):139-42 PMID: 11694251
  50. The origin and mechanism of circulating DNA.
    Ann N Y Acad Sci. 2000 Apr;906:161-8 PMID: 10818614
  51. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
    Clin Cancer Res. 2009 Apr 15;15(8):2630-6 PMID: 19351754
  52. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
    Cancer Discov. 2013 Jun;3(6):658-73 PMID: 23729478
Article Info
Journal
Genome biology
Abbr.
Genome Biol
ISSN
1474-760X
DOI
10.1186/s13059-014-0449-4
Published
2014-08-30
Epub
2014-00-30
Pages
449
Language
English
Region
England
NLM ID
100960660
PMCID
PMC4281953
Subset
IM
External Links
PubMed source DOI: 10.1186/s13059-014-0449-4 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2